The patient population with a rising prostate specific antigen (PSA) post-therapy with no evidence of disease on standard imaging studies currently represents the second largest group of prostate cancer patients. Little information is still available regarding the specificity and sensitivity of positron emission tomography (PET) tracers in the assessment of early biochemical recurrence. Ideally, PET imaging would allow one to accurately discriminate between local vs nodal vs distant relapse, thus enabling appropriate selection of patients for salvage local therapy. The vast majority of studies show a relatively poor yield of positive scans with PSA values o4 ng ml
Disease recurrence following definitive therapy for clinically organ-confined prostate cancer is not uncommon. The patient population with a rising prostate specific antigen (PSA) post-therapy, in fact, currently represents the second largest group of prostate cancer patients. 1 These patients have, by definition, a rising marker with no evidence of disease on standard imaging studies. 2 The median amount of time that a patient will spend in this state before developing overt metastatic disease is 8 years, with death occurring at a median of 5 years after clinical progression. 3 However, biochemical recurrence represents a wide spectrum of clinical risk. Some patients already harbour subclinical metastatic disease that will rapidly progress distantly, while others only experience locally persistent disease, with an otherwise indolent clinical course.
Several parameters have been tested to prognostically assess the individual course of the disease and different nomograms for prediction of tumour recurrence have been developed and validated for various treatment modalities. [4] [5] [6] [7] After radical surgery, PSA is expected to fall below the detection limit and recurrences should be suspected at the earliest rise in PSA. [8] [9] [10] Post-prostatectomy salvage radiotherapy has been shown to be of benefit when performed with low PSA, possibly as soon as failure is detected. [11] [12] [13] Salvage radiotherapy, with post-surgical PSA values 41 ng ml
À1
, is known to result in poor outcome. 12 Such a narrow PSA window clearly poses a significant diagnostic challenge for imaging studies whose aim is to discriminate between local relapse and distant disease to optimally tailor treatment strategy.
Following definitive radiotherapy, the optimal definition of biochemical failure still remains a matter of debate. An ASTRO consensus statement of 1997 defined relapse as the occurrence of three consecutive PSA rises. 14, 15 Retrospective analysis showed that the original ASTRO criterion had a sensitivity and specificity in the prediction of clinical failure of 60 and 72%, respectively. 16 Recently, other definitions have been shown to be more sensitive and specific than the ASTRO criterion, namely PSA greater than current nadir plus 3 ng ml À1 (sensitivity 76% and specificity 72%), dated at the call, PSA greater than absolute nadir plus 2 ng ml À1 (sensitivity 72% and specificity 70%), dated at the call, or two consecutive increases of at least 0.5 ng ml
, back dated (sensitivity 69% and specificity 73%). 16 In the light of the suboptimal sensitivity and specificity provided by current definitions, the ideal time for salvage treatment after biochemical relapse following definitive radiotherapy still remains a matter of debate.
The PSA doubling time has been found to correlate with poor outcome following both surgery and radiotherapy. [17] [18] [19] Patients with a low PSA doubling time (412 months) may be amenable to a salvage approach due to a lower likelihood of distant disease. 19 However, a rational treatment decision-making demands that satisfactory visual knowledge of the location and extent of the disease is acquired.
Transrectal ultrasound-guided biopsies have often been recommended in the rising PSA setting postprostatectomy. However, the rate of histological confirmation is less than 30% at PSA levels o1 ng ml À1 . 20 The yield of detection increases significantly with higher PSA levels, where salvage radiotherapy becomes of lesser benefit. Moreover, biopsy-proven confirmation of local recurrence, even at low PSA values, does not rule out the presence of loco-regional or distant spread. 21 Therefore, the recommendation for salvage radiotherapy is generally based on pathologic T-stage, PSA nadir time, time to biochemical relapse and PSA doubling time. This ultimately results in a certain number of patients being treated with intensive local therapy unnecessarily, because of the presence of occult metastasis. All traditional imaging methods, especially at low PSA values, have low sensitivity and specificity. 22, 23 At the local level, conventional imaging methods may fail to discriminate between recurrent tumour and fibrosis after surgery and/or radiation therapy. 24 Metabolic imaging by positron emission tomography (PET) has been proposed as a possible solution to overcome the limitations of traditional anatomic imaging. Recently, hardware-fused PET/computed tomography (CT) is emerging as a diagnostic tool with increased sensitivity and specificity rates than either modality alone. 25, 26 The promises of novel PET tracers in the setting of early evaluation of prostate cancer relapse lie on their potential ability to discriminate between postsurgical and post-radiation changes vs viable disease, as well as between local relapse only vs nodal and/or distant disease. Indeed, the most critical question for the rising PSA population is not that whether residual disease is detected in the prostate/prostatic fossa, but rather about the status of distant disease. Even if an imaging study could detect local disease with a 100% sensitivity and specificity, clinical decision-making would be strongly influenced by the lack of diagnostic accuracy in the status of distant disease.
There is still relatively scarce information in the literature regarding the specificity and sensitivity of PET tracers in the assessment of patients with biochemical recurrence following primary local therapy (Table 1) . 18 F-FDG-PET in the rising PSA setting has led to controversial results. Hofer et al. 35 concluded that 18 F-FDG is useless for the detection of local recurrence after radical prostatectomy. This may be explained by the fact that this tracer undergoes renal excretion with subsequent accumulation in the urinary bladder, which may cause artefacts in the lower pelvis. Recently, this technical problem has been significantly reduced by newer iterative reconstruction algorithms. 36 Using this method, Turlakow et al. 36 reported a high correlation between positive 18 F-FDG-PET findings and biopsyproven presence of disease in patients with primary or recurrent disease. In a recent analysis, however, Schö der et al. 23 were able to detect disease in the prostate bed in only 5 of 21 patients. Overall, 18 F-FDG-PET was shown to be true positive in 31% of cases only (local and/or distant failure).
The role of newer PET tracers in the detection of local relapse in the rising PSA setting is also rather controversial. This is largely due to the fact that these studies have been conducted with heterogeneous and relatively small patient populations. Moreover, PET findings have been histologically confirmed only in a limited number of cases. In the majority of the studies, PET results were simply compared to other diagnostic techniques. The results of these studies should therefore be interpreted with great caution.
11 C-choline PET was evaluated in the post-treatment follow-up of 32 patients (20 post-surgery and 16 post-RT) by de Jong et al. 29 All of 14 patients with no biochemical relapse after therapy were found to be PET negative. Twenty-two patients had biochemical recurrence. PET was true positive in 5/13 (38%) of cases in the postsurgical setting and in 5/9 (78%) cases following external beam radiotherapy. Histological proof of recurrence, however, was not obtained in all cases.
Picchio et al. , postprostatectomy local, nodal and bone recurrences were detected in 7, 33 and 7% of patients, respectively. In the post-irradiation setting, 62% of patients had positive PET findings in the prostate. Nodal uptake and bone metastases were observed in 38 and 13% of cases, respectively.
Similarly, Sandblom et al. 30 in a group of 20 patients with biochemical relapse following prostatectomy with a median PSA of 2 ng ml À1 showed pathologic uptake of 11 C-acetate in 75% of cases. In 40% of this patient cohort, a solitary lesion was detected. All patients with a PSA level of X2 ng ml À1 had a positive scan with either local or systemic disease. At PSA o2 ng ml À1 , however, positive findings were observed in 44% of the cases (three local recurrences and one nodal metastasis). No correlations with other diagnostic studies were reported. In 10 cases, a biopsy of the region of tracer uptake was performed, only 4 of which had histological confirmation of recurrent disease.
Recently, Albrecht et al. 31 evaluated the role of 11 Cacetate in 32 patients with an early PSA relapse following either definitive radiotherapy (17 cases) or prostatectomy (15 cases). In the post-irradiation setting, an SUV max X2 was used as a cutoff. With a median PSA value of PET imaging in biochemical relapse C Greco et al PET imaging in biochemical relapse C Greco et al
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Prostate Cancer and Prostatic Diseases 6 ng ml À1 at the time of PET, local recurrence was detected in 82% (14/17) of cases. PET was positive in five of six biopsy-proven recurrences. In the post-surgical setting, PET was interpreted visually and was considered positive in five cases. The median PSA at the time of PET in this group was 0.4 ng ml À1 and 11/15 patients had values o0.8 ng ml
À1
. In eight post-surgical patients, a positive biopsy was obtained. Of these, only three had been considered PET positive.
Cimitan et al. 32 evaluated the potential of PET/CT and 18 F-fluoromethylcholine in the assessment of biochemical recurrence after primary treatment. One hundred consecutive patients with a persistent increase in PSA following radical prostatectomy (58), radiotherapy (21) or hormonal therapy alone (21) were evaluated. Positive scans were observed in 54% of cases, mostly in patients with PSA values 44 ng ml
. Of the negative scans, 89% were observed in patients with PSA o4 ng ml
. Whether the regions of tracer uptake actually represent true or false positives cannot be determined from any of the above studies (with the exception, of course, of the instances in which lesions were biopsied). In the study by Kotzerke et al., 28 however, 31 patients with biochemical relapse following prostatectomy were studied with 11 Cacetate scans and the results were compared to transrectal ultrasound combined with biopsy of the prostatic bed. PET was positive in 15 of 18 (83%) patients with local recurrence confirmed at biopsy. No focal uptake was demonstrated in the prostate bed in the 13 patients with a negative biopsy. A similar systematic study in the post-irradiation PSA relapse setting has not yet been reported.
Methodological issues regarding the assessment of locally residual disease
Ideally, in order to establish how well PET tracers can detect persistence/recurrence of local disease, preprostatectomy studies should be performed comparing PET findings with pathology in an adequately powered cohort of patients. In the definitive radiotherapy setting, this information could also become the basis for studies on selective boosting of dominant lesions in the prostate by means of the metabolic and spatial information provided by appropriately chosen PET tracers. 38, 39 So far, limited information on PET detectability of the primary disease in patients with biopsy-proven prostate cancer is available. Using a PET/CT scanner and 11 C-choline, Martorana et al. 40 reported a sensitivity of 83% for lesions 45 mm in size in patients who underwent radical prostatectomy. Similarly, Reske et al. 41 reported an accuracy of 84% in the detection of prostate segments containing cancer confirmed at pathology using a segmental SUV max 42.65. Similar results have been reported by Kwee et al. 42 using a dual phase 18 F-choline PET technique. Yamaguchi et al. 43 compared 11 C-choline to MR and MR spectroscopy in the detection of prostate lesions in patients with biopsy-proven disease before radical prostatectomy. Using SUV max , PET exhibited a diagnostic sensitivity of 100%. An asymmetrical uptake in the prostate, indicating the site of the primary lesion, was visualized in all patients studied. Sensitivities of MR and MRI spectroscopy were 60 and 65%, respectively. Regarding the precise location of the primary lesion, 11 C-choline PET results were in agreement with pathological findings in 83% of cases vs 50% with MR spectroscopy.
Correlation studies between 11 C-acetate PET findings for the primary prostatic disease and post-prostatectomy pathology are not available yet. Oyama et al.
44 compared 11 C-acetate to 18 F-FDG in a small patient cohort with biopsy-proven and mostly locally advanced prostate cancer. Sensitivity was 100% for 11 C-acetate (no accumulation in the urine) and 83% with 18 F-FDG (due to tracer retention in the bladder). 44 The relatively high proportion of 18 F-FDG prostate positivity in this study was explained by the advanced stage of the majority of cases.
In the post-irradiation early PSA relapse setting, a large prospective study dealing with the sensitivity and specificity of PET, with a systematic bioptic assessment of the PET findings, is still lacking. The outcome of such a study may provide important information on the optimal salvage approach and on the feasibility of imageguided selective prostate re-treatment by further radiation therapy (brachytherapy or external beam).
Assessment of nodal status
The presence of positive pelvic lymph-node metastasis in prostate cancer has traditionally been associated with poor prognosis. 45 Recently, the notion of oligometastasis is being developed around the concept that, under certain circumstances, metastases may be a limited, localized process. 46 Solitary or numerically limited pelvic nodal lesions, in the context of biochemical relapse and with low PSA doubling time may, indeed, fall under this category. Potentially, if imaging could provide evidence of discrete pelvic nodal site, then, local treatment, such as image-guided high-dose radiotherapy, could be rationally advocated. Figure 1 shows an instance of a solitary PET-positive pelvic nodal area in a patient with biochemical relapse with both 18 F-FDG and 18 F-choline. Currently, no imaging modality is able to accurately detect lymph-node metastasis in patients with early biochemical recurrence following primary local therapy.
CT and MRI have been invariably shown to suffer from low sensitivity in the evaluation of nodal metastasis in prostate cancer staging, due to the inability of crosssectional imaging to detect metastasis in normal-sized nodes. 47 High resolution MR imaging with lymphotrophic super paramagnetic nanoparticles is a promising technique in the detection of occult nodal metastasis in nodes measuring 5-10 mm with a sensitivity of 100% and a specificity of 95.7% on a per patient basis in the preprostatectomy setting. 48 However, these outstanding results have not been confirmed in patients with biochemical relapse.
The potential usefulness of PET imaging in detecting lymph-node metastasis in prostate cancer in the preoperative setting has been shown in a large prospective study by de Jong et al. 49 Sensitivity, specificity and accuracy of 11 C-choline in the detection of nodal metastasis were reported to be 80, 96 and 93%, respectively, suggesting that this tracer has a higher sensitivity than that of CT or MRI. 49 However, the role of PET imaging in the assessment of nodal metastasis in patients with a rising PSA is still rather controversial.
Seltzer et al. compared the detection ability of metastatic nodal disease by CT, 18 
F-FDG-PET and monoclonal
111 Indium capromab pendetide (Prostascint) in patients with elevated PSA after treatment for localized prostate cancer. 18 F-FDG-PET was positive for distant disease in 50% patients with PSA 44, and only in 4% with PSA o4 ng ml
À1
. Both CT and 18 F-FDG-PET were considered of limited value for detecting nodal disease in patients with a low PSA or low PSA velocity. Prostascint had an even lower detection rate. Other recent reports suggest that Prostascint is not fulfilling its promise and is of little incremental value in selecting patients with local recurrence who may be salvaged by radiotherapy. 50 Chang et al. 51 evaluated the role of 18 F-FDG-PET in patients with rising PSA following treatment for localized prostate cancer who had a negative bone scan. Patients underwent lymph-node dissection following PET. At the sites of histopathologically proven metastases, increased 18 F-FDG uptake was found in 75% of patients. In a recent analysis, Scattoni et al.
33 assessed the ability of 11 C-choline PET/CT to detect nodal metastasis in patients with post-surgical biochemical recurrence through histological confirmation of PET findings by lymphadenectomy. Ninety percent (19/21) of patients with biochemical recurrence (median PSA 1.98 ng ml À1 ) with evidence of lymph-node metastasis on 11 C-choline PET had histological confirmation. None of the patients with positive CT or MRI and a negative 11 C-choline PET were found to have positive lymph nodes on pathological evaluation. A lesion-based analysis showed that 11 C-choline PET/CT had a sensitivity of 64%, a specificity of 90%, a positive predictive value of 86%, a negative predictive value of 72% and an accuracy of 77%.
Impact of PSA level on PET imaging findings
Since PSA level reflects tumour burden, a PSA threshold below which no imaging finding is obtained can be expected. Schö der et al. 23 showed that the proportion of The results of the correlation of 11 C-choline PET findings, SUV, and PSA from various studies are controversial. In the study by de Jong et al., 49 no positive findings were obtained with 11 C-choline PET in patients with PSA recurrence o5 ng ml À1 . Scattoni et al., 33 however, reported a sensitivity and specificity of 64% and 85% at PSA o2 ng ml À1 in the detection of nodal disease. Using 11 C-acetate, Oyama et al. 27 were not able to detect recurrent tumours in patients with a rising PSA at levels o3 ng ml À1 . Also with 11 C-acetate, Sandblom et al.
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reported positivity with a median value of 2.5 ng ml À1 vs a median value of 1.1 for no uptake. Heinisch et al., 52 using 18 F-choline, reported the presence of at least one focus of uptake in 47% of patients with a rising PSA o5 ng ml À1 . In their study, Cimitan et al. 32 found that the majority of positive scans occurred in patients with PSA 44 ng ml À1 and concluded that 18 F-fluoromethylcholine PET/CT is not likely to have a significant impact on the therapeutic management of patients with biochemical recurrence until this level is reached. However, a role may be envisaged in the selection of patients with higher PSA values to exclude distant metastasis when salvage local treatment is feasible.
The low yield of PET generally reported with PSA levels o2 ng ml À1 may be explained by its low spatial resolution (approximately 0.5 cm) and by the low burden. However, it may be speculated that other biological mechanisms, such as the proliferation rate of the disease, may be involved in the uptake of the tracers.
The fact that no tracer has so far been shown to be able to detect local recurrence within the critical 1 ng ml
À1
PSA threshold clearly limits the use of PET imaging in the post-surgical setting for the purpose of patient selection for salvage prostatic fossa irradiation. However, PET imaging in biochemical relapse C Greco et al preliminary evidence suggests that 11 C-choline PET may be useful in selecting out patients with early biochemical relapse (PSA o2 ng ml
) who have pelvic nodal oligometastasis potentially amenable to local treatment. 33 The correlation between different PET-tracers and PET findings with reference to PSA levels should be studied in large patient groups in order to optimize criteria for patient referral.
Choice of PET tracer
Some reports have indicated a superiority of newer tracers over 18 F-FDG in the detection local and nodal relapse. 27, 37 Large studies comparing 18 F-FDG with other tracers in terms of yield for distant visceral and bone recurrences, however, are still lacking.
Direct intraindividual comparison of 11 C-choline and 11 C-acetate in prostate PET imaging is limited to a small pilot study in which the potential of both radiotracers to detect known bone lesions, lymph-node metastases and imaging of the primary was shown to be identical. 53 One of the main drawbacks of using 11 C-labeled tracers is the relatively short half-life of the isotope (T 1/2 ¼ 20 min), which limits their use to centers with on-site cyclotrons. This has led to the development of 18 F-labeled analogues of choline whose biodistribution has been shown to be similar to that of 11 C-choline. 54, 55 However, 18 F-choline differs strikingly from 11 C-choline, in that it shows significantly higher secretion in the urinary system, which may pose diagnostic limitations in the lower pelvis, which is the most critical anatomical site in prostate cancer imaging. No information is yet available on the role of 18 F-choline in the evaluation of patients with rising PSA.
Recently Vees et al. 34 assessed the value of PET/CT with 18 F-choline and 11 C-acetate in 20 consecutive patients with a rising PSA (o1 ng ml À1 ) following radical prostatectomy with a similar yield of positive scans with the two tracers.
Proper patient selection is needed to make the most of any imaging study in prostate cancer. 2 For instance, 18 F-FDG may be superior and more cost effective for the detection of distant disease, whereas 11 C-acetate or 11 C-choline may prove more accurate in identifying local recurrence and/or nodal metastasis. Thus, rather than simply replacing a tracer with another, a multitracer approach may be needed to fully exploit the potential of PET imaging in the setting of biochemical failure.
23,56

Conclusions
The role of PET imaging in prostate cancer is gradually evolving but still remains within the experimental realm. Well-conducted studies comparing the merits of different tracers are still lacking. Prospective trials to further assess the value of currently available PET tracers are warranted to determine their ultimate role in prostate cancer management both as imaging tools and as potential prognostic factors. The search for new, more specific markers of prostate cancer by the use of oncogenomic techniques should also be carried out with the aim to improve the diagnostic accuracy of this imaging modality.
